Pharmaceutical Giant Faces Mounting Challenges as Analyst Turns Bearish

Danish pharmaceutical leader Novo Nordisk is confronting significant headwinds as market sentiment shifts dramatically. Morgan Stanley has issued a stark reassessment of the company’s prospects, downgrading its rating and slashing the price target substantially.

In a move that caught market attention, Morgan Stanley analyst Thibault Boutherin reduced Novo Nordisk’s rating from “Equal Weight” to “Underweight” – effectively recommending investors sell their positions. The firm simultaneously cut its price target from $59 to $47, representing a substantial 20% reduction.

The downgrade reflects growing concerns about prescription trends for Novo Nordisk’s flagship medications Ozempic and Wegovy in the United States, where growth has stalled after a period of remarkable expansion.

Competitive Pressures Intensify Across Markets

Morgan Stanley’s... Read more...